Nature Medicine, Published online: 19 October 2026; doi:10.1038/s41591-026-04692-0
In a multiomic analysis of samples from patients with newly diagnosed multiple myeloma treated with isatuximab, carfilzomib, lenalidomide and dexamethasone induction therapy followed by consolidation treatment guided by minimal residual disease (MRD) status, baseline genomic, transcriptomic and epigenetic features are associated with MRD status after induction.
